- Email: [email protected]
135 HYPERTHERMIA RADIOSENSITIZES HYPOXIC HCT-116 HUMAN COLORECTAL CARCINOMA CELLS IN VITRO
S60 was used. For both intra- and inter-registration modalities both NC (for intra-) and MI (for inter-) featurelets algorithm showed animprovement when compared to the iPlan software, although the result was statistically significant only for the inter-modality approach (MI(69.72 +/- 4.88)% VS iPlan(57.90 +/6.23)% oVOI values), giving a p-value of 0.02 when the MI method was use. Conclusions: The featurelets deformable registration algorithm provided promising results for both validation configurations showing comparable, if not better, results with already widely used commercially available algorithms for deformable registration.
ICTR-PHE 2012 Johannesma M, Lutgens L, Lammering G, van Mastrigt GA, De Ruysscher DK, Lambin P, van der Zee J. Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006269.
135 HYPERTHERMIA RADIOSENSITIZES HYPOXIC HCT-116 HUMAN COLORECTAL CARCINOMA CELLS IN VITRO A. Staab, I. Müller, J. Rudner, V. Heinrich, M. Bamberg, S. Huber Department of Radiooncology, Eberhard-KarlsUniversity, Tübingen, Germany Background: Hypoxia has been linked to tumor progression and poor prognosis. Hyperthermia is a sentizer of cell killing by ionizing radiation (IR). The aim of the present study was to investigate whether hyperthermia affects hypoxia-induced radioresistance in HCT-116 human colorectal carcinoma cells in vitro. Material and Methods: HCT-116 human colorectal carcinoma cells were maintained in a humidified incubator at 37°C and 5% CO2. For incubation under hypoxic conditions, exponentially growing cells were placed into the hypoxic chamber for 24h (GasPak 100, Becton-Dickinson, Heidelberg, Germany). Severe hypoxic conditions (<0.1% O2) were reached after 60 min. as indicated by a methylene blue indicator inserted into the system (Becton-Dickinson, Heidelberg, Germany). Cells were assayed for clonogenic survival (two independent experiments; three dishes/ experiment) after irradiation (RT) with 2Gy under hypoxic (Hyp) and normoxic conditions in combination with/without hyperthermia (42.0°C/1h in a humidified incubator). Results: Hyperthermia (HT) did not significantly affect the survival fraction (SF) under normoxic and hypoxic conditions [SFControl vs. SF HT: 100% vs. 105.8% ± 4.0 % (p > 0.05); SFHyp vs. SFHyp/HT: 87.6% ± 5.2% vs. 75.0% ± 3.5% (p > 0.05)]. HT has no effect on radiosensitivity of HCT-116 cells under normoxic conditions compared to tumor cells treated with RT alone [Figure 1: SF_2Gy vs. SF_2GyHT: 39.3% ± 2.1% vs. 32.5% ± 1.3% (p > 0.05)]. Under hypoxic conditions, clonogenic survival was significantly increased after single dose RT as compared to normoxia [Figure 1: SF_2Gy vs. SF_ 2GyHyp: 39.3% ± 2.1% vs. 48.2% ± 1.4% (p < 0.05)]. Most importantly, HT enhanced significantly radiation treatment efficacy under hypoxic conditions compared to hypoxic tumor cells treated with RT alone [Figure 1: SF_2GyHyp/HT vs. SF_2GyHyp: 16.2% ± 1.6% vs. 48.2% ± 1.4% (p < 0.05)]. Conclusion: We could demonstrate that HT reduces hypoxic radioresistance in HCT116 cells in vitro confirming earlier observations that HT increases the response to radiotherapy in patients with locally advanced rectal cancer[1]. References: 1: De Haas-Kock DF, Buijsen J, Pijls-
Figure 1: Clonogenic survival after treatment with HT under normoxic and hypoxic conditions in HCT116human colorectal carcinoma cells 136 REAL-TIME MONITORING OF THE BRAGG PEAK DURING ION THERAPY: RECENT DEVELOPMENTS OF THE BEAM DETECTION SYSTEM M. De Rydt1,2, M. Chevallier2, D. Dauvergne2, S. Deng2, G. Dedes5, N. Freud4, J. Krimmer2, J.-M. Létang4, H. Mattez2, M. Pinto2, C. Ray2, M.-H. Richard2,3, F. Roellinghoff2, V. Reithinger2, E. Testa2, Y. Zoccaratto2 1 Instituut voor Kern- en Stralingsfysica, K.U.Leuven, Belgium 2 IPNL, Université de Lyon, F-69003 Lyon, France; 3 Université Lyon 1 and CNRS/IN2P3, UMR 5822, F-69622 Villeurbanne, France 4 CREATIS, Université de Lyon, F-69622 Lyon, France; Université Lyon 1 and CNRS UMR 5220; INSERM 5 Max Planck Institut für Physik, München The use of high-energy charged-particle beams in tumor therapy requires an accurate monitoring of the Bragg peak, i.e. the pronounced maximum of the dose distribution at the end of the ion range. To control the extremely localised position of the Bragg peak and to confine it to the tumor volume, the development of a real-time imaging system is indispensable. Dose monitoring techniques currently under development in our collaboration make use of the secondary protons and prompt gamma’s, emitted during the fragmentation processes in the patient’s body [1-5]. In general, the path and the origin of the secondary particles are reconstructed using the position and the energy deposited in one or more detectors. Of great assistance in the 3D reconstruction process of the ion-matter interaction point is the knowledge of the transverse coordinates of the incoming therapy ion. These coordinates can be obtained by intercepting the beam with a hodoscope, a beam monitoring device consisting of closely spaced scintillating fibers in the horizontal and vertical directions. Another main feature of the hodoscope is its fast timing output. In combination with a fast detector signal, it is possible to discriminate different types of secondary
ICTR-PHE 2012 Johannesma M, Lutgens L, Lammering G, van Mastrigt GA, De Ruysscher DK, Lambin P, van der Zee J. Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006269.
135 HYPERTHERMIA RADIOSENSITIZES HYPOXIC HCT-116 HUMAN COLORECTAL CARCINOMA CELLS IN VITRO A. Staab, I. Müller, J. Rudner, V. Heinrich, M. Bamberg, S. Huber Department of Radiooncology, Eberhard-KarlsUniversity, Tübingen, Germany Background: Hypoxia has been linked to tumor progression and poor prognosis. Hyperthermia is a sentizer of cell killing by ionizing radiation (IR). The aim of the present study was to investigate whether hyperthermia affects hypoxia-induced radioresistance in HCT-116 human colorectal carcinoma cells in vitro. Material and Methods: HCT-116 human colorectal carcinoma cells were maintained in a humidified incubator at 37°C and 5% CO2. For incubation under hypoxic conditions, exponentially growing cells were placed into the hypoxic chamber for 24h (GasPak 100, Becton-Dickinson, Heidelberg, Germany). Severe hypoxic conditions (<0.1% O2) were reached after 60 min. as indicated by a methylene blue indicator inserted into the system (Becton-Dickinson, Heidelberg, Germany). Cells were assayed for clonogenic survival (two independent experiments; three dishes/ experiment) after irradiation (RT) with 2Gy under hypoxic (Hyp) and normoxic conditions in combination with/without hyperthermia (42.0°C/1h in a humidified incubator). Results: Hyperthermia (HT) did not significantly affect the survival fraction (SF) under normoxic and hypoxic conditions [SFControl vs. SF HT: 100% vs. 105.8% ± 4.0 % (p > 0.05); SFHyp vs. SFHyp/HT: 87.6% ± 5.2% vs. 75.0% ± 3.5% (p > 0.05)]. HT has no effect on radiosensitivity of HCT-116 cells under normoxic conditions compared to tumor cells treated with RT alone [Figure 1: SF_2Gy vs. SF_2GyHT: 39.3% ± 2.1% vs. 32.5% ± 1.3% (p > 0.05)]. Under hypoxic conditions, clonogenic survival was significantly increased after single dose RT as compared to normoxia [Figure 1: SF_2Gy vs. SF_ 2GyHyp: 39.3% ± 2.1% vs. 48.2% ± 1.4% (p < 0.05)]. Most importantly, HT enhanced significantly radiation treatment efficacy under hypoxic conditions compared to hypoxic tumor cells treated with RT alone [Figure 1: SF_2GyHyp/HT vs. SF_2GyHyp: 16.2% ± 1.6% vs. 48.2% ± 1.4% (p < 0.05)]. Conclusion: We could demonstrate that HT reduces hypoxic radioresistance in HCT116 cells in vitro confirming earlier observations that HT increases the response to radiotherapy in patients with locally advanced rectal cancer[1]. References: 1: De Haas-Kock DF, Buijsen J, Pijls-
Figure 1: Clonogenic survival after treatment with HT under normoxic and hypoxic conditions in HCT116human colorectal carcinoma cells 136 REAL-TIME MONITORING OF THE BRAGG PEAK DURING ION THERAPY: RECENT DEVELOPMENTS OF THE BEAM DETECTION SYSTEM M. De Rydt1,2, M. Chevallier2, D. Dauvergne2, S. Deng2, G. Dedes5, N. Freud4, J. Krimmer2, J.-M. Létang4, H. Mattez2, M. Pinto2, C. Ray2, M.-H. Richard2,3, F. Roellinghoff2, V. Reithinger2, E. Testa2, Y. Zoccaratto2 1 Instituut voor Kern- en Stralingsfysica, K.U.Leuven, Belgium 2 IPNL, Université de Lyon, F-69003 Lyon, France; 3 Université Lyon 1 and CNRS/IN2P3, UMR 5822, F-69622 Villeurbanne, France 4 CREATIS, Université de Lyon, F-69622 Lyon, France; Université Lyon 1 and CNRS UMR 5220; INSERM 5 Max Planck Institut für Physik, München The use of high-energy charged-particle beams in tumor therapy requires an accurate monitoring of the Bragg peak, i.e. the pronounced maximum of the dose distribution at the end of the ion range. To control the extremely localised position of the Bragg peak and to confine it to the tumor volume, the development of a real-time imaging system is indispensable. Dose monitoring techniques currently under development in our collaboration make use of the secondary protons and prompt gamma’s, emitted during the fragmentation processes in the patient’s body [1-5]. In general, the path and the origin of the secondary particles are reconstructed using the position and the energy deposited in one or more detectors. Of great assistance in the 3D reconstruction process of the ion-matter interaction point is the knowledge of the transverse coordinates of the incoming therapy ion. These coordinates can be obtained by intercepting the beam with a hodoscope, a beam monitoring device consisting of closely spaced scintillating fibers in the horizontal and vertical directions. Another main feature of the hodoscope is its fast timing output. In combination with a fast detector signal, it is possible to discriminate different types of secondary